Nasdaq

MediWound Announces Positive Top-Line Results from Its Pivotal Phase 3 Study (DETECT) in NexoBrid® for Eschar Removal of Severe Thermal Burns

Conference call with MediWound management and U.S. key opinion leader begins today, January 22, 2019 at 10:00 a.m. Eastern time YAVNE, Israel, Jan. 22, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd.
Nasdaq

MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults

Full commercial launch of NexoBrid marks important first step to becoming the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns YAVNE, Israel, ...
streetinsider

MediWound (MDWD) Phase 3 Pediatric Study (CIDS) of NexoBrid for Eschar Removal of Severe Thermal Burns Mets Primary Endpoints

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here. MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on ...